NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Amarin Corp. Plc\uk AMRN
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$213.6M
▼ 6.5% vs FY2024
EPS · FY25
$-0.09
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-8.2%
Net margin · FY25
-18.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 213.6M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 18 cents on every revenue dollar this year.
Per share
USD -0.09
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-8.2%
Return on equity, FY2025
ROE
Operating margin-23.5%
Net margin-18.2%
Return on assets-5.7%
Each USD of equity lost 8 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−19.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−16.7%
−19.0%
+10.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.42B
Shares outstanding, FY2025
Change, 5 years+6.0%
Change, 10 years+126.9%
The share count grew 6% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 670.8M
total assets, end of FY2025
Total assetsUSD 670.8M
EquityUSD 459.3M
CashUSD 134.7M
Current ratio3.34×
Equity funds 68% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.2
0.2
0.3
0.4
0.6
0.6
0.4
0.2
0.2
0.1
0.1
0.1
0.0
·
·
·
·
Operating income $B
−0.1
−0.1
−0.1
−0.1
0.0
−0.0
−0.0
−0.1
−0.0
−0.1
−0.1
−0.1
−0.2
−0.1
−0.0
−0.0
−0.0
EBITDA $B
·
−0.1
−0.1
−0.1
0.0
−0.0
−0.0
·
−0.0
−0.1
−0.1
−0.1
−0.2
−0.1
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
−0.0
Net income $B
−0.0
−0.1
−0.1
−0.1
0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.2
−0.2
−0.1
−0.2
−0.0
EPS, diluted $
−0.09
−0.20
−0.15
−0.26
0.02
−0.05
−0.07
−0.39
−0.25
−0.41
−0.83
−0.36
−1.28
−1.24
−0.53
−2.49
−0.72
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−8.2
−15.8
−10.3
−16.8
1.2
−2.9
−6.0
−267.0
·
·
·
·
·
·
·
·
−407.7
Shares out B
0.42
0.41
0.41
0.41
0.40
0.39
0.36
0.33
0.27
0.27
0.18
0.17
0.17
0.15
0.14
0.11
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
56 of 56
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed